Results 141 to 150 of about 742,802 (244)
Arthritis &Rheumatology, EarlyView.Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
Attacking the public health crisis of hepatocellular carcinoma at its roots
Hepatology, EarlyView., 2022 Abstract As the third most common cause of cancer‐related death worldwide with significant mortality rates in the United States, hepatocellular carcinoma has strong association with cirrhosis and chronic hepatitis B virus (HBV) with a growing at‐risk population from the rise in chronic liver disease from alcohol use and nonalcoholic fatty liver disease.
Hannah M. Lee +3 more
wiley +1 more source
Hepatitis risk assessment tool [PDF]
"Hepatitis" means inflammation of the liver and is usually caused by a virus. In the U.S., the most common types are Hepatitis A, Hepatitis B, and Hepatitis C.
core
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Arthritis &Rheumatology, EarlyView.Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz +13 more
wiley +1 more source
Health disparities in chronic liver disease
Hepatology, EarlyView., 2022 Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian +3 more
wiley +1 more source
Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors
British Journal of Clinical Pharmacology, EarlyView.Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem +5 more
wiley +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim Non‐surgical treatment of acute liver failure (ALF) is primarily supportive and depends on the underlying cause. While N‐acetylcysteine (NAC) is proven effective in paracetamol‐induced ALF, its potential benefits in non‐paracetamol ALF for paediatric patients remain unclear.
Alise D. E. de Groot +7 more
wiley +1 more source
Identification of novel neutralizing determinants for protection against HCV
Hepatology, EarlyView., 2022 Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua +12 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Background Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce.
Montserrat Laguno +13 more
wiley +1 more source